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Mycophenolic acid (MPA) is an effective treatment for active
lupus nephritis despite its variable efficacy in different ethnic
groups. Here we tested whether pharmacokinetic monitoring
may help to optimize dosing of MPA in an Asian population.
Patients with biopsy-proven class III or IV lupus nephritis
(ISN/RPS category) were treated with mycophenolate mofetil
or enteric-coated mycophenolate sodium. One month after
initiating treatment we measured plasma MPA levels in eight
samples taken over a 12-h period after drug administration.
The mean area under the time-dependent curve for MPA of
responding patients was significantly higher than those not
responding. Successful treatment was seen in patients with
areas445mgh/l. The dosage of the drug was not related to
MPA pharmacokinetics. In the mycophenolate mofetil group,
however, MPA-area under the curve was positively, and
significantly, correlated with trough or 1h after dose
concentrations and associated with a therapeutic response.
Thus, our study shows that MPA pharmacokinetics were
positively correlated with therapeutic responses of
mycophenolate, suggesting that controlling the
concentrations may improve its therapeutic efficacy in lupus
nephritis. As the absorption and pharmacokinetic peak of
enteric-coated tablets is slower, it is important to take
different formulations into account when determining
optimal MPA concentrations.
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Proliferative lupus nephritis (International Society of
Nephrology/Renal Pathology Society class III/IV categoriza-
tion) is the most common and serious complications of
systemic lupus erythematosus (SLE). Without the appro-
priate treatment, this complication can turn into an end-
stage kidney disease within a few months. The standard of
care for lupus nephritis is cyclophosphamide and steroids,
even though it has many drug-related adverse events.1 The
most common causes of death for SLE patients are fatal
infections acquired in consequence of using immunosup-
pressive therapy.2 Therefore, a more effective and safer
treatment for lupus nephritis is needed.
Recently, the first-line treatment for proliferative lupus
nephritis cyclophosphamide was replaced by mycophenolate
mofetil (MMF), because its efficacy was comparable and less
toxic.3–10 Furthermore, results from a recent multicenter,
randomized-controlled study showed that African Americans
responded poorly to cyclophosphamide.6 In contrast, the
results from the Aspreva Lupus Management Study showed
that Asians responded equally well to both MMF and
cyclophosphamide, even though there were more deaths
reported in the MMF group.11 It should be noted that the
Aspreva Lupus Management Study trial was the largest
multinational study in lupus nephritis, which increased target
MMF dose to 3 g per day. Although most studies used 2 g per
day of MMF,1,3,4 the high-targeted MMF dose in this Aspreva
Lupus Management Study trial may be too much, particu-
larly for Asians. It has been pointed out that ethnicity may
partly explain the different pharmacokinetic profiles seen in
MMF and variation in the treatment responses.6,11 Therefore,
therapeutic drug monitoring (TDM) study may help to
optimize dosing of MMF in different ethnicities.
It has been shown that TDM of mycophenolic acid (MPA)
can improve clinical outcomes in organ transplant recipients.12
Acute rejection rate was reduced in kidney allograft recipients,
who had achieved MPA therapeutic levels consistently and early
after transplantation. Similar to that observed in organ trans-
plant recipients, severe lupus nephritis also requires early and
maximal therapeutic efficacy to stop the inflammation process.
As MMF became the mainstay immunosuppressive drug with
steroid minimization, thus we determined the correlation
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between the MPA levels of MMF or enteric-coated (EC)-
mycophenolate sodium (MPS) and its therapeutic response in
patients with proliferative lupus nephritis.
RESULTS
Patient characteristics
Out of a total of 18 patients, 2 patients were recently
diagnosed with proliferative lupus nephritis, whereas the rest
had renal relapse. In all, 15 patients had received cyclopho-
sphamide therapy in the previous episodes of renal flare
(Table 1). All patients had either class III or IV lupus
nephritis at the time of enrollment. In addition, five patients
had class IVþV lupus nephritis. A total of 12 patients were
treated with MMF and 6 patients received EC-MPS.
After 6 months of mycophenolate therapy, 11 patients
responded to treatment (responders) and 7 patients did not
(nonresponders). The responder and nonresponder groups
were generally comparable in age, body mass index, duration
of lupus nephritis, disease activity, serum creatinine,
estimated glomerular filtration rates, serum albumin, 24-h
urinary protein, exposure to steroid, cyclophosphamide or
ACEI/ARB, and renal pathological indices (Table 1).
MPA–area under the concentration–time curve (AUC)
predicted the response to the therapy
The mean (s.d.) MPA–AUC of the responders was signifi-
cantly higher than the nonresponders (65.98 (23.77) versus
32.08 (7.97); P¼ 0.002) (Figure 1). The MPA–AUC level
above 45mg h/l can precisely predict the patient’s response to
therapy. With respect to treatment response, the receiver–-
operator characteristic curve (ROC) depicted the true-
positive fractions (sensitivity) and false-positive fractions
(1–specificity) at various cut points for MPA–AUC levels
(Figure 2a). The calculated area under the ROC curve was
0.96 (95% confidence interval¼ 0.87–1.05). On the other
hand, the therapeutic responses can not be predicted on the
basis of daily doses of MMF or EC-MPS or other clinical
parameters such as renal histology indices, pretreatment
levels of urinary protein, serum complement, or estimated
renal function (Figure 2b). The ROC–AUC and 95% con-
fidence interval were 0.20(0.05–0.45), 0.25(0.01–0.51), 0.66
(0.38–0.94), 0.40(0.10–0.71), 0.65(0.37–0.93), 0.53(0.23–0.84),
and 0.63(0.33–0.92) for urine protein, SLE disease activity
index (SLEDAI), systolic blood pressure, estimated glomerular
filtration rate, serum albumin, complement level, and activity
Table 1 | Comparisons between responder and nonresponder groups in demographics, laboratory results, and treatments
received during the study
Patient characteristics All (N=18) Responders (n=11) Nonresponders (n=7)
Sex, female: male 16:2 10:1 6:1
Age, years 33±7.76 34±9.42 31±4.1
Body mass index 22.2±4.04 20.6±1.4 24.5±5.49
Duration of disease, years 7.5±4.68 7.5±4.79 7.4±4.89
SLEDAI-2K score 15±4.01 14.4±4.4 17±3.26
Serum creatinine (mg/dl) 1.26±0.56 1.37±0.66 1.09±0.33
eGFR (CG) (ml/min) 70.71±42.91 62.14±35.67 84.18±52.45
eGFR (MDRD) (ml/min) 69.94±42.09 65.02±39.23 77.66±48.38
Serum albumin (g/dl) 2.6±0.70 2.8±0.73 2.3±0.58
24-h urine protein (g/day) 6.3±4.42 4.8±3.38 8.7±5.0
Hemoglobin level (g/dl) 10.5±1.86 10.3±1.77 10.7±2.13
White blood cell (cell/mm3) 9144±4703 10,443±4665 7102±4296
Serum total bilirubin (mg/dl) 0.29±0.07 0.33±0.05 0.25±0.06
ISN/RPS classification
Class III, n 4 2 2
Class IV, n 9 6 3
Class IV+V, n 5 3 2
Activity index (0–24) 12±4.84 12±4.95 11±4.96
Chronicity index (0–12) 3±2.07 2±1.95 3±2.06
Dosage of steroid at baseline (mg/d) 39±19.67 43±21.5 32±15.61
Dosage of steroid at 6 months (mg/d) 9±1.61 9±2.24 9±2.48
Cumulative dosage of steroid (mg) 3400±461 3175±646 3738±668
Number of patients on MMF/EC-MPS 12/6 8/3 4/3
Dosage of MMF (mg) 1416±194.63 1375±231.45 1500±0.0
Dosage of EC-MPS (mg) 1260±197.18 1080±0 1440±0
Dosage of MMF (mg)/IBW (kg) 28.07±5.39 27.69±5.85 28.84±5.05
Dosage of EC-MPS (mg)/IBW (kg) 25.37±7.19 19.24±3.4 31.51±2.17
Patients formerly received CY (n) 13 7 6
Number of patients on ACEI/ARB 13 8 5
Abbreviations: ACEI/ARB, angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker; AUC, area under the concentration–time curve; CG, Cockcroft–Gault; CY,
cyclophosphamide; EC, enteric coated; eGFR, estimated glomerular filtration rate; IBW, ideal body weight; ISN/RPS, International Society of Nephrology/Renal Pathology
Society; MDRD, Modification of Diet in Renal Disease; MMF, mycophenolate mofetil; MPA, mycophenolic acid; SLEDAI, SLE disease activity index.
All P-values for comparison (responder vs nonresponder) were 40.05.
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index, respectively. A value of 0.5 (reference line) is no better
than by chance and a value of 1.0 reflects a perfect indicator.
According to the MPA–AUC target levels used in organ
transplantation, patients with MPA–AUC levels of 460,
between 30 and 60 ando30mg h/l had response rates of 100,
60, and 0%, respectively, (P¼ 0.02) (Figure 3).
Association between plasma MPA concentrations at trough
(C0) or 1 h after dose (C1) and response to therapy with MMF
In the MMF group, the plasma concentration of MPA at
trough, 1, 4, and 8 h after dose were significantly correlated
with MPA–AUC (r¼ 0.90, 0.92, 0.70, and 0.80, respectively;
all Po0.05) (Table 2, Figure 4). On the other hand, there was
no correlation between each single-time point of MPA levels
and MPA–AUC in the EC-MPS group.
Interestingly, the plasma MPA concentrations at trough
and 1 h after dose (C1) in the MMF group were associated
with the response to MMF therapy. The mean C0 and C1 of
the responders were significantly greater than the nonrespon-
ders (3.09±1.07 versus 1.23±0.85; P¼ 0.01 and 24.48±
11.82 versus 5.96±3.93mg/l; P¼ 0.01). However, there were
overlapping data of individual C0 and C1 levels between both
the groups (Figure 5).
Adverse events
Majority of the patients reported one or more adverse events.
Common events were gastrointestinal events, hematotoxicity
(anemia or leucopenia), and infection, which occurred in 50,
28, and 11% of the patients, respectively. There were no life-
threatening adverse events. MPA–AUC was not associated
with infectious episodes, gastrointestinal, or hematological
adverse events (Table 3).
DISCUSSION
This study showed, for the first time, the association between
MPA exposure and its therapeutic efficacy for active lupus
nephritis. Favorable treatment response rates, without any
additional adverse events, were associated with MPA–AUC
above 45mg h/l. This study showed a pivotal role of TDM of
MPA for the treatment of lupus nephritis. ROC analysis
(Figure 2) showed that the MPA–AUC was far superior as
compared with other clinical or laboratory profiles in
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Figure 1 |Mycophenolic acid (MPA)–area under the
concentration–time curve (AUC) levels and the response to
therapy. Bars and lines represent the means and s.e. of the
MPA–AUC levels. The responder (white bar) had significantly
higher MPA–AUC levels than the nonresponder (black bar). AUC of
MPA (0–12 h).
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Figure 2 |Receiver–operator characteristic curve (ROC) curves
of mycophenolic acid (MPA)–area under the concentration
–time curve (AUC) levels to predict the response to therapy.
The fraction of true-positive (sensitivity) and that of false-positive
results (1specificity) for (a) MPA–AUC and (b) other parameters
as predictors of the response to therapy are shown. The area
under the curve of ROC curve was 0.96 for MPA–AUC. The area
under the curves of ROC curves were 0.20, 0.40, 0.65, 0.53, and
0.63 for urine protein, estimated glomerular filtration rate (GFR),
serum albumin, complement level, and activity index.
A value of 0.5 (reference line) is no better than by chance and a
value of 1.0 reflects a perfect indicator.
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Figure 3 |Patients with high mycophenolic acid (MPA)–area
under the concentration–time curve (AUC) levels have better
therapeutic response rates. Patients were divided into three
groups on the basis of their MPA–AUC levels of o30, 30–60, and
460mgh/l.
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predicting therapeutic responses. Furthermore, MPA–AUC
was not associated with dosages of MMF or EC-MPS.
Therefore, a direct measurement of blood MPA levels in each
patient is required to determine MPA exposure.
On the basis of results obtained from transplant recipients,
it has been suggested that TDM of MPA should be carried out
to minimize the risk of allograft rejection.13 In a randomized
controlled trial known as APOMYGRE, it was shown that
TDM of MPA can reduce risks of allograft rejection and
treatment failure in renal transplant recipients.12 In organ
transplantation, the target therapeutic levels of MPA–AUC
was above 45mg h/l.12 When we used this value for our study,
we noticed that it can precisely predict a good response to
therapy as well. Similarly, MPA–AUC of 30–60mg h/l and
460mg h/l that were used for transplantation,13 when used
in this study, were associated with increased response rates
(60 and 100%, respectively) as well.
It should be noted that reports from transplant recipients
recommended having TDM of MPA carried out at several
time points because of its large inter-subject variability in
MPA exposure.14 There are many factors that may influence
the large inter-subject variability seen in MPA pharmaco-
kinetics such as renal impairment, liver dysfunction, hypo-
albuminemia, genetic factors, and concurrent use of
calcineurin inhibitors.14–16 As we did not aim to test
influences of these factors, therefore in our study, our sample
size was too small to answer this type of question.
Nevertheless, our results showed MPA at trough levels and
1 h after dose were closely associated with MPA–AUC in
patients receiving MMF. This finding is consistent with
studies conducted in patients with autoimmune diseases and
glomerulopathy.17–19 Neumann et al.20 conducted a pharma-
cokinetic study comparing autoimmune disease with kidney
transplantation, which showed a better correlation at a
single-time point and full AUC for autoimmune disease.
Along the same lines, another study showed that high MPA
trough levels (C0) in SLE patients receiving MMF treatment
had lower recurrent rates.19
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Figure 4 |Correlation between area under the concentration–time curve (AUC) and single-time point of plasma mycophenolic
acid (MPA) levels from patients taking mycophenolate mofetil (MMF, n¼ 12). (a) The relationship between the AUC and C0
was significant at Po0.001 (r¼ 0.90). (b) The relationship between the AUC and C1 was significant at Po0.001 (r¼ 0.92). (c) The relationship
between the AUC and C4 was significant at Po0.01 (r¼ 0.70). (d) The relationship between the AUC and C8 was significant at Po0.01
(r¼ 0.80). C0, C1, C4, C8: plasma concentrations of MPA at trough, 1, 4 and 8 h after dose, respectively.
Table 2 | Pharmacokinetic parameters of mycophenolic acid
(MPA) after oral administration of 1–1.5 g/day MMF and
1080–1440mg/day EC-MPS in patients with class III or IV
lupus nephritis
MMF (n=12) EC-MPS (n=6)
Parameters Means±s.d. Means±s.d.
C0 (mg/l) 2.47±1.33 2.73±1.46
C0.5 (mg/l) 7.08±7.16 2.68±1.46
C1 (mg/l) 18.3±13.28 2.02±0.7
C2 (mg/l) 6.72±2.26 7.48±5.83
C3 (mg/l) 4.05±2.64 6.23±4.85
C4 (mg/l) 3.37±2.11 3.59±1.99
C8 (mg/l) 3.38±2.19 2.92±2.04
C12 (mg/l) 2.59±1.9 2.14±1.54
AUC012 (mgh/l) 57.97±29.38 42.44±9.86
Cmax (mg/l) 19.43±12.01 10.12±5.13
Tmax (h) 1.54±1.03 3.25±2.52
Dosage (mg/day) 1416.67±194.63 1260±197.18
Dosage/IBW (kg) 28.07±5.39 25.37±7.19
Abbreviations: AUC0–12, area under the concentration–time curve for 0–12 h; Cmax,
maximum concentration of drug; C0, trough plasma concentration of mycophenolic
acid; C0.5, C1, C2, C3, C4, C8, and C12, plasma concentrations of mycophenolic acid at
0.5, 1, 2, 3, 4, 8 and 12 h post-dose, respectively; EC-MPS, enteric-coated
mycophenolate sodium; IBW, ideal body weight; MMF, mycophenolate mofetil;
Tmax, maximum drug concentration.
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In addition, our study confirmed that pharmacokinetic
profiles of MPA were different between MMF and EC-MPS.
The maximum MPA level had an earlier peak for MMF.
These results indicated that the drug absorption of EC-MPS
was slower and its pharmacokinetic peak was consistent with
that of EC-formulated tablets. Therefore, it is important to
take different tablet formulations in to account when
determining optimal TDM of MPA.21
Aside from that, we demonstrated that there was a positive
correlation between MPA trough levels or at 1 h after dose
and the therapeutic response to MMF, even though there was
an overlapping data for the MPA levels (Figure 5). This
finding is in contrast to the results obtained from the renal
transplant recipients, which showed weak correlations
between MPA–AUC and trough level of MPA.22,23 It was also
pointed out that MPA trough levels obtained from renal
transplant recipients were not specific and sensitive in
predicting acute rejection compared with MPA–AUC.24–28
This difference may be because of the fact that our lupus
nephritis patients were only on MPA therapy without
concomitant use of other immunosuppressive drugs. Other
differences such as degree of renal impairment and serum
albumin levels may have contributed to this discrepancy.
Taking in to account our participants’ mild degree of renal
impairment and almost normal serum albumin levels, we
noticed that these different factors did not significantly
influence the pharmacokinetics of MPA.
The limitation of this study is our small sample size.
Although this study may not be applicable to majority of the
lupus patients, however, these results are relevant to those
patients with class III or IV lupus nephritis. The immuno-
suppressive use in this study was relatively low dose of MPA
with corticosteroids. In order to validate the benefit of MPA
exposure in an immunosuppressive regimen, we had to use
high doses of MPA without steroid. Another limitation of the
study is that the pharmacokinetic profiles of MPA were
assessed only once during the 6-month period. These results
could not determine within-patient variability. However, it
has been shown that there was minimal within-patient
variability in patients taking MMF after transplantation.14
On the other hand, multiple blood samplings of MPA–AUC
may maximize the efficacy and minimize its toxicity but
repeated measurements of MPA levels in real life is not
practical and feasible. Therefore, single point or limited
sampling strategies have been proposed to monitor MPA in
the blood.
Despite these limitations, our study showed that MPA
exposure is a good predictor for early therapeutic responses
in patients who have biopsy-proven class III or IV lupus
nephritis. Thus, we recommend maintaining MPA–AUC
levels above 45mg h/l in severe lupus nephritis patients
taking mycophenolate treatment. It is important that MPA
monitoring is carried out to ensure optimal dosing of the
immunosuppressive drug in lupus patients.
MATERIALS AND METHODS
Patients and study design
This 6-month prospective study enrolled Thai patients with SLE as
defined by the criteria of American College of Rheumatology.29
Renal biopsy showed proliferative lupus nephritis class III or IV
according to the 2003 International Society of Nephrology/Renal
Pathology Society classification.30 All participants were required to
have any combinations of the two clinical criteria present: (1) 24-h
urine protein 42 g/day, (2) active-urine sediments (red blood cells
45 or white blood cells 45 per high-power field) or estimated
glomerular filtration rate o60ml/min, and/or (3) a biopsy-
confirmed diagnosis of ISN/RPS class III/IV LN within 12 weeks
of study.
Patients were treated with a fixed dose of 1.0–1.5 g per day of
MMF or 1080–1440mg per day of EC-MPS for 6 months based on
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Figure 5 |Plasma mycophenolic acid (MPA) concentrations at
trough (C0) or 1 h after dose (C1) and the response to therapy
with mycophenolate mofetil (MMF). Dots and lines represent
the individual and means of the MPA levels. (a) The responder
(n¼ 8) had significantly higher MPA trough levels than the
nonresponder (n¼ 4). Likewise, (b) the mean MPA level at 1 h after
dose was higher in the responder.
Table 3 | Number of MPA-related adverse events for three
different MPA–AUC levels
MPA–AUC (mgh/l)
Adverse events Patients N (%) o30 30–60 460
GI symptoms 9 (50%) 2 4 3
Hematological symptoms 5 (28%) 1 1 3
Infections 2 (11%) 1 0 1
Total 18 (100%) 3 10 5
Abbreviations: AUC, area under the concentration–time curve for 0–12 h; GI
symptoms, gastrointestinal symptoms such as diarrhea, nausea, vomiting; hemato-
logical symptoms, anemia (Hbo11 g/dl) and leucopenia (white blood cell count
o4000/mm3); infection, Herpes infection; MPA, mycophenolic acid.
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the physicians’ prescription. The highest dose was given within
2 weeks and then no dose change was allowed unless there was
intolerance. All patients received oral prednisolone; starting dose of
prednisolone was 0.7mg per kg of body weight per day and this dose
was reduced every 2 weeks by 5mg/day until the dose was 5mg/day.
A short course (o2 weeks) of moderate steroid dose (o30mg/d)
was allowed in one patient (responder group) because of presenta-
tion of hemolytic anemia. The pharmacokinetic study was
performed after 1 month of treatment. We excluded patients who
were pregnant or had serum creatinine 43mg/dl. Those who were
nonadherent to the protocol or had a history of mycophenolate
treatment, gastrointestinal disorders, or concurrent administration
of medications that disturbed the MPA pharmacokinetics such as
antacids, cholestyramine, acyclovir, and rifampin, were excluded
from the study as well. The participants were asked to take the
medicine on time with a 12 h interval and at least 1 h apart from
meals. Drug pill count was carried out by the study team at every
clinic visit. The follow-up period was for 6 months.
The study was approved by the Ethics Committee for Human
Research, Faculty of Medicine, Chulalongkorn University, Bangkok,
Thailand, and written informed consents were obtained from all the
participants.
The pharmacokinetic study of MPA
We measured MPA plasma levels 1 month after initiating
mycophenolate treatment. Venous blood samples were drawn at
baseline, 30min, 1, 2, 3, 4, 8, and 12 h after oral administration of
mycophenolate. A volume of 3ml of blood was collected in an
ethylenediaminetetraacetic acid-treated vaccutainers and was cen-
trifuged at 1200 g for 15min. All plasma samples were stored at
801C until further analysis was carried out.
MPA plasma concentration was measured by the new enzymatic
method (Roche Total MPA Assay, Hoffmann-La Roche, Basel,
Switzerland) on the basis of inhibition of inosine monophosphate
dehydrogenase, the in vivo target of MPA. It is a rapid and reliable assay
for determining plasma MPA concentrations when compared with the
standard assays of LC–MS/MS. The method can be performed using
fully automated COBAS INTEGRA analyzers and using the Cobas
modular platform (Roche Diagnostics GmbH) in combination with
routine clinical chemistry. Results can be obtained in 20min.31,32 The
area under the plasma concentration–time curve (MPA–AUC) was
calculated by using the linear trapezoidal rule. We assessed whether
there was any relationship between single-time point and MPA–AUC.
Patient outcome assessment
The primary outcome of the study was to assess the correlation
between MPA–AUC and treatment response. This was defined by the
following criteria: (1) have a normal or increased estimated
glomerular filtration rate by 25% if the baseline estimated
glomerular filtration rate was abnormal, (2) have inactive-urine
sediments (red blood cells o5 cells per high-power field and white
blood cells o5 cells per high-power field), and (3) have a 50%
reduction of 24-h urine protein resulting in a levelo2 g/day.33 The
secondary objectives assessed the number of adverse events and their
association with the drugs studied. Serum creatinine, complete
blood count, serum albumin, liver function test, fasting blood sugar,
lipid profiles, anti-nuclear antibodies, anti-double-stranded DNA,
complement levels, and 24-h urine protein were assessed at baseline
and the 6th month of treatment. Glomerular filtration rates were
estimated using the Modification of Diet in Renal Disease study
equations34 and the Cockcroft–Gault formula.35 All patients under-
went medical history and physical examination, which included
measurements of systolic and diastolic pressure, body weights, and
vital signs. All adverse effects of mycophenolate were recorded.
Statistical analyses
This study had an 80% power to detect a 40% difference in mean
MPA–AUC between responders and nonresponders with an a error
of 0.05 (two-sided). According to the power or sample-size
calculations, 18 patients were needed. We enrolled a total of 20
patients into the study, among whom 2 were excluded at the
screening visit. Statistical analyses were performed by using the SPSS
software version 16 (SPSS Inc., Chicago, IL, USA). Continuous data
were tested for normal distribution by using Kolmogorov–Smirnov
and Shapiro–Wilks tests. The normally distributed continuous data
were expressed as mean and standard deviation (s.d.) unless
otherwise specified. Differences in mean MPA–AUC in responders
and nonresponders were analyzed by an independent sample t-test.
To predict therapeutic response, ROC of MPA–AUC levels was
analyzed. The area under the curve was calculated. After the
therapeutic ranges in kidney transplantation,13 MPA–AUC was
categorized into three ranges (o30, 30–60mg h/l, and460mg h/l),
and the response rates of the patients from the three different groups
were compared by using Chi-square test. Pearson’s correlation
analysis was used to determine whether there was any correlation
between MPA–AUC and each single-point level of MPA plasma
concentration. a was set at 0.05 and all tests were two-sided.
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